Rivus Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.rivuspharma.com
Relative Bioavailability Study of HU6
- Conditions
- Healthy
- Interventions
- Drug: HU6 150 mg Capsules x 3 (Total dose = 450 mg)Drug: HU6 450 mg Tablet
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06486558
- Locations
- 🇺🇸
Nucleus Network, Saint Paul, Minnesota, United States
A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6
- Conditions
- Healthy
- Interventions
- Drug: [14C]-HU6
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT06325930
- Locations
- 🇺🇸
Pharmaron Clinical Pharmacology Center (CPC), Baltimore, Maryland, United States
Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes
- Conditions
- Diabete Type 2Obesity
- Interventions
- Drug: HU6
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Registration Number
- NCT06104358
- Locations
- 🇺🇸
AdventHealth Translational Research Institute, Orlando, Florida, United States
Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
- Conditions
- Fatty LiverNon-Alcoholic Fatty Liver DiseaseNonalcoholic Steatohepatitis
- Interventions
- Other: PlaceboDrug: HU6
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 219
- Registration Number
- NCT05979779
- Locations
- 🇺🇸
Velocity Clinical Research, Los Angeles, California, United States
🇺🇸Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸CenExel HRI, Berlin, New Jersey, United States
Safety and Pharmacokinetics of HU6
- Conditions
- Obese
- Interventions
- Drug: HU6 TabletDrug: HU6 Capsule
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05433506
- Locations
- 🇺🇸
Nucleus Network, Minneapolis, Minnesota, United States
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: PlaceboDrug: HU6
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT05284617
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance, California, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: HU6Drug: Placebo
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT04874233
- Locations
- 🇺🇸
Prism Clinical Research, Minneapolis, Minnesota, United States
Multiple Ascending Dose Study of HU6 in High BMI Volunteers
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: HU6
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2021-08-16
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04709913
- Locations
- 🇺🇸
Prism Clinical Research, Minneapolis, Minnesota, United States
Ascending Dose Study of HU6 in Healthy Volunteers
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: HU6
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Rivus Pharmaceuticals, Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT04463017
- Locations
- 🇺🇸
Prism Clinical Research, Saint Paul, Minnesota, United States